{
    "nctId": "NCT01930292",
    "briefTitle": "Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies",
    "officialTitle": "A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC)",
    "overallStatus": "TERMINATED",
    "conditions": "Solid Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Part A: Number of participants with dose-limiting toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Meets protocol-specified criteria for qualification and contraception\n* Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications\n* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures\n\nExclusion Criteria:\n\n* Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters\n* Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:\n\n  1. the safety or well-being of the participant or study staff;\n  2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); or\n  3. the analysis of results",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}